Replies to post #93686 on Biotech Values

[dewophile]

not sure what you mean - my post had nothing to do with what the market would do short term or even idix for that matter - i simply felt the nvs relationship was complicating negotiations on 184
i think if the POC on 320 goes as planned, then the maximum value for 184 can then be attained in some package deal
Q4 of this year could be very interesting for IDIX with POC on 3 compounds in the bag - and if they retain rights then a buyout or major licensing could materialize imo